Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Roche Holding AG | 2,307 |
| 2 | Bristol Myers Squibb Co | 1,896 |
| 3 | Pfizer Inc | 1,317 |
| 4 | Novartis AG | 1,305 |
| 5 | Abbott Laboratories | 1,157 |
| 6 | AstraZeneca PLC | 1,144 |
| 7 | Merck and Co Inc | 1,079 |
| 8 | Takeda Pharmaceutical Co Ltd | 1,038 |
| 9 | Gilead Sciences Inc | 952 |
| 10 | University of California | 779 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 70,161 |
| 2 | A61K | Medicinal preparations | 69,523 |
| 3 | C07D | Heterocyclic compounds | 23,205 |
| 4 | C07K | Peptides | 22,840 |
| 5 | C12N | Microorganisms, enzymes | 10,028 |
| 6 | G01N | Investigating / analysing materials | 8,888 |
| 7 | Y02A | Climate change adaptation | 5,040 |
| 8 | C12Q | Measuring/testing involving enzymes | 4,416 |
| 9 | A61L | Sterilising / disinfecting materials | 3,834 |
| 10 | C07C | Acyclic and carbocyclic compounds | 3,553 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use | 2003 | AbbVie Inc | 505 |
| Bis-anthracyclines with high activity against doxorubicin resistant tumors | 1999 | 98 | |
| Derivatives of doxorubicine, their preparation and use | 1981 | 74 | |
| Preparation of injectable doxorubicin/liposome suspension | 1990 | 61 | |
| Liposome/doxorubicin composition and method | 1990 | Hadassah Medical Organization | 52 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 1,699 |
| 2017 | 1,725 |
| 2018 | 1,780 |
| 2019 | 1,830 |
| 2020 | 1,827 |
| 2021 | 1,615 |
| 2022 | 1,501 |
| 2023 | 1,251 |
| 2024 | 1,406 |
| 2025 | 623 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Gabriel N. Hortobágyi | The University of Texas MD Anderson Cancer Center | 91 |
| 2 | Aman U. Buzdar | Breast Cancer Care | 48 |
| 3 | Andrew V. Schally | Tulane University | 44 |
| 4 | Randy D. Gascoyne | BC Cancer Agency | 43 |
| 5 | Joseph M. Connors | BC Cancer Agency | 42 |
| 6 | Karel Ulbrich | Czech Academy of Sciences, Institute of Macromolecular Chemistry | 41 |
| 7 | Andreas Engert | University Hospital Cologne | 39 |
| 8 | Gianni Bonadonna | Fondazione IRCCS Istituto Nazionale dei Tumori | 37 |
| 9 | Tomáš Etrych | Czech Academy of Sciences, Institute of Macromolecular Chemistry | 34 |
| 10 | Xuesi Chen | Chinese Academy of Sciences | 32 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Regulation of Ferroptotic Cancer Cell Death by GPX4 | 2014 | 7741 | Ferroptosis and cancer prognosis |
| Calreticulin exposure dictates the immunogenicity of cancer cell death | 2006 | 3147 | Autophagy in Disease and Therapy |
| Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line | 1992 | 3060 | DNA and Nucleic Acid Chemistry |
| Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems | 2012 | 2470 | Nanoparticle-Based Drug Delivery |
| Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals | 2007 | 2455 | Wnt/β-catenin signaling in development and cancer |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Doxorubicin?
Which organizations hold the most patents related to Doxorubicin?
What are some common trade names or synonyms for Doxorubicin?
What research topics are most prominently associated with Doxorubicin publications?
How has the patent filing rate for Doxorubicin-related inventions changed in recent years?